Category: Treatment Access News
PrEP listed on the Ontario public formulary
CTAC warmly welcomed the news that Pre-Exposure Prophylaxis, or PrEP, will be listed on the Ontario Public Formulary as of September 28 2017. It will be listed as a general benefit for those using it to prevent HIV infection and the move represents a large step forward in the fight against HIV in Ontario. read more
BC delays PrEP rollout
PrEP is proven to be a highly effective way of preventing new HIV infections. The newsthat the BC Ministry of Health have not put a date on rolling out public coverage means that the people most likely to be exposed to HIV are unlikely to have access to PrEP. read more
Gilead receives approval in Canada for VOSEVI™ for re-treatmenet of certain patients with chronic hepatitis C virus (HCV) infection
Gilead Sciences Canada, Inc. (Gilead Canada) today announced that Health Canada has granted a Notice of Compliance for VOSEVI™ (sofosbuvir 400 mg/velpatasvir 100 mg/voxilaprevir 100 mg) tablets read more
ABBVIE’s MAVIRET™ approved by Health Canada for the treatment of chronic hepatitis C in all major genotypes.
AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced that Health Canada has granted approval for MAVIRET™ (glecaprevir/pibrentasvir tablets), a once-daily, ribavirin-free treatment for adults with chronic hepatitis C virus (HCV) infection across all major genotypes (GT1-6). read more